CRIS Archived Articles
Curis Inc. (NASDAQ:CRIS): Pioneering IRAK4 Inhibition in Hematological Malignancies
Published on March 13, 2025
Curis Inc (NASDAQ:CRIS): A Biotech Focused on Innovative Cancer Treatments
Published on November 30, 2024
Curis (NASDAQ:CRIS) Reports Promising Progress in Advancing Emavusertib Across Key Hematological Malignancies
Published on September 24, 2024